For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...
Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes normal inflammatory and immune responses, the p19 and ...
Hosted on MSN5d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis PatientsJohnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback